BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. BriaCell Therapeutics Corp. is best known for its cell-based oncology programs, including Bria-IMT, a lead therapy being studied for metastatic breast cancer, along with Bria-OTS, a personalized off-the-shelf immunotherapy platform, and Bria-PROS+ for prostate cancer. The company also works on BriaDx, a diagnostic tool designed to support patient selection for its immunotherapy approaches. Its current business centers on advancing cancer treatment candidates through clinical development, with an emphasis on breast cancer and other solid tumors. Based in West Vancouver, Canada, BriaCell Therapeutics Corp. operates within the immuno-oncology segment of the healthcare market, where it develops novel therapeutic and diagnostic assets aimed at improving how cancer is detected and treated.
WebsiteBellevue Centre
West Vancouver, BC, V7T 2X1
Canada
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approachPhase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOB
Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026” PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering C
BriaCell Therapeutics (NASDAQ:BCTX) shares experienced a volatile session on Monday after the biotechnology company announced that its Bria-MEL+ melanoma vaccine candidate had reached an important genetic engineering milestone. The stock initially jumped 25% following the announcement before surrendering those gains later in the session, highlighting the market’s shifting reaction to the development-stage programme.
Investors talking about BCTX also mention
What share of all stock conversation is about BCTX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% +0 | 0% 0 | 0% 0 | 0% -0.01 |
Of the messages about BCTX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 62.5% | 62.5% -37.5 | 93.88% +1.97 | 84.66% +3.38 | ||
| Bearish | 37.5% | 37.5% new | 6.12% -1.97 | 15.34% -3.38 |
Of the messages about BCTX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 92.98% | 76.5% | ||
| Technical Analysis | — | 0% | 7.02% | 7.74% | ||
| Analysts | — | 0% | 0% | 10.41% | ||
| Controversies | — | 0% | 0% | 0% | ||
| Earnings | — | 0% | 0% | 0% | ||
| Macro | — | 0% | 0% | 5.34% |
Of the messages about BCTX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 66.67% | 50.88% | 65.65% | 60.14% | ||
| Newcomers | 33.33% | 49.12% | 34.35% | 39.86% |